疏肝化浊振阳方治疗慢性前列腺炎合并勃起功能障碍的临床观察  

Clinical Efficacy of Shugan Huazhuo Zhenyang Prescription in Treatment of Chronic Prostatitis Combined with Erectile Dysfunction

作　　者：严祖桢 赵宗江[2] YAN Zuzhen;ZHAO Zongjiang(Beijing Chaoyang Jinzhan Second Community Health Service Center,Beijing 100018,China;Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]北京朝阳区金盏第二社区卫生服务中心,北京100018 [2]北京中医药大学,北京100029

出　　处：《中国实验方剂学杂志》2025年第8期135-142,共8页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家重点研发计划项目(2018YFC1704304);北京市朝阳区中医药薪火传承学术经验暨特色技术继承工程项目(2018-228)。

摘　　要：目的:探讨疏肝化浊振阳方治疗慢性前列腺炎(CP)合并勃起功能障碍(ED)患者的临床疗效。方法:该研究为随机对照研究,从赵宗江教授门诊中收集90例CP合并ED患者,按照1∶1随机分入治疗组和对照组,各45例。治疗组的治疗方案为疏肝化浊振阳方,对照组的治疗方案为枸橼酸西地那非片,治疗周期均为4周。在治疗前后分别纳入患者的基线资料,包括年龄、体质量指数(BMI)、病程等,对两组临床疗效、慢性前列腺炎症状评分(CPSI)、国际勃起功能问卷(IIEF-5)、勃起硬度评分(EHS)、中医证候评分及前列腺液常规变化进行对比分析,评估两组治疗对CP合并ED患者的有效性及安全性。结果:两组患者一般资料差异无统计学意义;与本组治疗前比较,治疗组患者治疗后的慢性前列腺炎症状评分(CPSI)、中医证候评分均明显降低(P<0.05),IIEF-5评分增加(P<0.05),EHS评级中Ⅲ级及Ⅳ级频数均明显增加(P<0.05);与对照组比较,CPSI评分及中医证候评分均明显降低(P<0.05),治疗后治疗组的临床疗效及IIEF-5评分虽较前改善,但差异无统计学意义;治疗后治疗组前列腺液中白细胞、红细胞、脓细胞均较对照组下降,卵磷脂小体较对照组升高(P<0.01)。两组安全性评价均未见明显异常。结论:疏肝化浊振阳方可以改善疼痛不适,排尿异常,阴囊潮湿,勃起不坚,早泄,阳痿等症状,有效治疗CP合并ED。Objective:To explore the clinical efficacy of Shugan Huazhuo Zhenyang prescription in treating patients with chronic prostatitis(CP)complicated by erectile dysfunction(ED).Methods:This study is a randomized controlled trial,which enrolled 90 CP patients with ED from Professor ZHAO Zongjiang's outpatient clinic.The patients were randomly divided into a treatment group and a control group in a 1∶1 ratio,with 45 patients in each group.The treatment group received the Shugan Huazhuo Zhenyang prescription,while the control group received Sildenafil citrate tablets.Both treatments lasted for 4 weeks.Baseline data,including age,body mass index(BMI),and disease duration,were collected before and after treatment.Clinical efficacy,chronic prostatitis symptom score(CPSI),international erectile function questionnaire(IIEF-5),erection hardness score(EHS),traditional Chinese medicine(TCM)syndrome score,and routine changes in prostate fluid were compared and analyzed between the two groups to evaluate the effectiveness and safety of the treatments for CP combined with ED.Results:There were no statistically significant differences in general information between the two groups.After treatment,the treatment group showed a significant decrease in the CPSI score and an increase in the IIEF-5 score(P<0.05).The differences in EHS ratings and TCM syndrome scores were statistically significant(P<0.05).Compared to the control group,there were significant differences in CPSI scores and TCM syndrome scores(P<0.05).Although the clinical efficacy and IIEF-5 score in the treatment group improved after treatment,the differences were not statistically significant.After treatment,the white blood cells,red blood cells,and pus cells in the prostate fluid of the treatment group decreased compared to the control group,while lecithin bodies increased.The differences between the two groups were statistically significant(P<0.01).No significant abnormalities were found in the safety evaluations.Conclusion:Shugan Huazhuo Zhenyang prescription can impro

关 键 词：慢性前列腺炎 勃起功能障碍 疏肝化浊振阳方 随机对照 临床研究 

分 类 号：R2-031[医药卫生—中西医结合] R287[医药卫生—中医学] R697.33